celecoxib has been researched along with aspirin in 220 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.36) | 18.2507 |
| 2000's | 128 (58.18) | 29.6817 |
| 2010's | 76 (34.55) | 24.3611 |
| 2020's | 13 (5.91) | 2.80 |
| Authors | Studies |
|---|---|
| Knaus, EE; McDonald, R; Praveen Rao, PN; Uddin, MJ | 1 |
| Chen, QH; Knaus, EE; Rao, PN | 1 |
| Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S | 1 |
| Brunhofer, G; Erker, T; Handler, N; Jaeger, W; Leisser, K; Parth, S; Studenik, C | 1 |
| Abdellatif, KR; Chen, QH; Chowdhury, MA; Dong, Y; Knaus, EE | 3 |
| Abdellatif, KR; Chowdhury, MA; Dong, Y; Knaus, EE | 2 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR; Velázquez, C | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Rahman, M; Suresh, MR | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR; Velázquez, C; Yu, G | 1 |
| Coy, ED; Cuca, LE; Sefkow, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Huang, Z; Knaus, EE; Rahman, M; Suresh, MR; Velázquez, CA; Yu, G | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Huang, Z; Knaus, EE; Suresh, MR; Velázquez, CA; Yu, G | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Abdur Rahim, M; Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Praveen Rao, PN | 1 |
| Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE | 1 |
| Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Sharma, SK; Wuest, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L | 1 |
| Bhatti, R; Kaur, M; Sharma, S; Singh, A; Singh, P | 1 |
| Boreddy, TS; Karpoormath, R; Palkar, MB; Rane, RA; Ronad, PM; Shaikh, MS; Singhai, AS; Veerapur, VP; Vishwanathswamy, AH | 1 |
| Bala, M; Bansal, S; Bhardwaj, V; Bhattacharya, S; Choudhary, S; Joseph, A; Singla, S; Suthar, SK | 1 |
| Abdellatif, KR; Azoz, AA; Elshemy, HA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdelall, EK; Kamel, GM | 1 |
| Abdelall, EKA; Ali, WAM; Lamie, PF | 1 |
| Guo, Z; Li, D; Li, J; Liu, X; Wang, L; Wu, L; Xu, Y; Yang, H | 1 |
| Ameen, BAH; Dissanayake, AA; Nair, MG | 1 |
| Kishore, N; Kumar, P; Shanker, K; Verma, AK | 1 |
| Chung, HY; Hong, J; Ju, Z; Jung, JH; Kim, S; La Kim, E; Moon, HR; Su, M | 1 |
| Abid, OU; Ahmad, A; Ahmad, S; Ayaz, M; Hussain, F; Jan, MS; Mahmood, F; Rashid, U; Sadiq, A; Ullah, F | 1 |
| Bhardwaj, A; Kaur, J; Wuest, F | 1 |
| Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S | 1 |
| Hawkey, CJ | 1 |
| Burke, A; FitzGerald, GA; Habib, A; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF | 1 |
| Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW | 1 |
| Fischer, R; Harrell, K; Marks, F | 1 |
| Bjarnason, I; Rainsford, KD | 1 |
| Balcázar-Muñoz, BR; González-Ortiz, M; Martínez-Abundis, E; Robles-Cervantes, JA | 1 |
| Bing, RJ; Johnson, PE; Kakar, NR; Vina, ER; Yamamoto, T | 1 |
| Bijlsma, JW; Lems, WF; van de Laar, MA | 1 |
| García Rodríguez, LA; Patrignani, P; Patrono, C | 1 |
| Gescher, AJ; O'Byrne, KJ; Sharma, RA; Steward, WP | 1 |
| Barrett, TD; Crofford, LJ; Driscoll, EM; Hennan, JK; Huang, J; Lucchesi, BR; Park, AM; Willens, DE | 1 |
| Nakamura, H | 1 |
| Cleland, LG; James, MJ; Penglis, PS; Stamp, LK | 1 |
| Nadackal, TG; Thomas, K; Thomas, T | 1 |
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| North, GL | 1 |
| Bing, RJ; Ingram, M; Miyataka, M; Rich, KA; Yamamoto, T | 1 |
| Sharma, RA | 1 |
| Kawano, S; Tsuji, S | 1 |
| Crofford, LJ | 1 |
| Clifford, LJ; Dewitt, DL; Nair, MG; Rana, J | 1 |
| Geis, GS | 1 |
| Stover, RR | 1 |
| Simon, RA; Stevenson, DD; Woessner, KM | 1 |
| Adler, R; Eskra, J; Noveck, R; Rushing, M; Vargas, R; Walden, C; Wilner, KD | 1 |
| Bradley, MD; Deeks, JJ; Smith, LA | 1 |
| Aspinall, AI; Beck, PL; Dort, J; Kilvert, VM | 1 |
| de Lima, OM; Dicay, M; Distrutti, E; Fiorucci, S; Ma, L; McKnight, W; Mencarelli, A; Morelli, A; Palazzetti, B; Romano, M; Wallace, JL | 1 |
| Calkin, AC; Dawood, T; Honisett, S; Komesaroff, PA; Sudhir, K; Williams, MR | 1 |
| Zeidler, H | 1 |
| Bartnik, W; Ostrowski, J; Skurzak, H; Wocial, T | 1 |
| Gyr, N; Lehmann, FS | 1 |
| Bauer, WM; Burke, CA; Lashner, B | 1 |
| Bochenek, G; Dahlén, B; Dahlén, SE; Drupka, D; Gyllfors, P; Isakson, PC; Kumlin, M; Lefkowith, JB; Mejza, F; Murray, JJ; Nizankowska, E; Overholt, J; Sheller, J; Szczeklik, A | 1 |
| Bing, RJ; Karouni, K; Lomnicka, M; Sue, M; Wessel, LA | 1 |
| Alfaya, T; Berges, P; Camacho, E; García-Rodriguez, R; Hinojosa, M; Martín-García, C | 1 |
| Burnier, M; Chiolero, A; Maillard, MP | 1 |
| del Soldato, P; Fiorucci, S; Morelli, A; Romano, M; Santucci, L; Sardina, M; Wallace, JL | 1 |
| Fernández, C; West, PM | 1 |
| George, A; Shakib, S | 1 |
| Mastalerz, L; Radziszewski, W; Setkowicz, M; Szczeklik, A; Zembowicz, A | 1 |
| Alvaro-Gracia, JM | 1 |
| Fiorucci, S; Perini, R; Wallace, JL | 1 |
| Alcindor, D; Kersten, JR; Krolikowski, JG; Pagel, PS; Warltier, DC | 1 |
| Coppelli, G; Coruzzi, G; Guaita, E; Spaggiari, S | 1 |
| Brunner, M; Gehrmann, M; Kremmer, E; Multhoff, G; Pfister, K; Reichle, A | 1 |
| Behm, A; Cox, ER; Fairman, KA; Frisse, M | 1 |
| Gazelle, GS; Hur, C; Simon, LS | 1 |
| Cirino, G; Di Lorenzo, A; Farneti, S; Fiorucci, S; Morelli, A; Renga, B | 1 |
| Fiorucci, S; Hollenberg, MD; von der Weid, PY; Wallace, JL | 1 |
| Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G | 1 |
| Bardou, M; Barkun, AN; Ghosn, J; Hudson, M; Rahme, E | 1 |
| Cryer, B | 1 |
| Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A | 1 |
| Wolfe, MM | 1 |
| Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S | 1 |
| Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Abadoğlu, O; Bavbek, S; Celik, G; Dursun, B; Misirligil, Z; Mungan, D; Paşaoğlu, G | 1 |
| Bresee, SJ; Carroll, RC; Chavez, JJ; Cohen, E; Craft, RM; Snider, CC | 1 |
| Cakir, N; Pamuk, ON | 1 |
| Allen, MJ; Fleming, I; McLean-Veysey, P | 1 |
| Whitehouse, MW | 1 |
| Abdallah, DM; El-Ghazaly, MA; Kelber, O; Khayyal, MT; Okpanyi, SN; Weiser, D | 1 |
| Couzin, J | 1 |
| Baldassarre, S; Choufani, G; Michils, A; Schandene, L | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Raskov, HH | 1 |
| Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X | 1 |
| Dodge, WE; Goldstein, JL; Lanza, FL; Lowry, SC; Schwartz, HI | 1 |
| Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH | 1 |
| Bardou, M; Barkun, AN; Dasgupta, K; Ghosn, J; Rahme, E; Toubouti, Y | 1 |
| Bijuklic, K; Colleselli, D; Kähler, CM; Mosheimer, BA | 1 |
| Huang, MH; Li, X; Ouyang, Q; Tang, CW; Wang, CH | 1 |
| Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG | 1 |
| Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M | 1 |
| Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M | 1 |
| Arthur, HM; Borthwick, GM; Burn, J; Johnson, AS; Partington, M; Wilson, R | 1 |
| Faber, J; Gawlewicz, A; Gielicz, A; Mastalerz, L; Sanak, M; Szczeklik, A | 1 |
| Hilário, MO; Len, CA; Terreri, MT | 1 |
| Chen, JT; Pucino, F; Resman-Targoff, BH | 1 |
| Ballmer-Weber, BK; Hofbauer, G; Roll, A; Schmid-Grendelmeier, P; Wüthrich, B | 1 |
| Bigler, J; Potter, JD; Ulrich, CM | 1 |
| Nedjar, H; Rahme, E | 1 |
| Dial, EJ; Lichtenberger, LM; Romero, JJ | 1 |
| Aglianò, AM; Frati, L; Gandini, O; Gazzaniga, P; Gianni, W; Gradilone, A; Morrone, S; Pulcinelli, FM; Scarpa, S; Silvestri, I | 1 |
| Cen, YY | 1 |
| Cmiel, A; Gawlewicz-Mroczka, A; Gielicz, A; Mastalerz, L; Sanak, M; Szczeklik, A | 1 |
| Alshafie, GA; Beebe-Donk, J; Harris, RE | 1 |
| Liu, XQ; Lou, JY; Luo, FM; Peng, ZL; Wang, HJ; Yang, KX | 1 |
| Aisenberg, J; Berger, MF; Dodge, WE; Goldstein, JL; Zakko, SF | 1 |
| Dayani, PN; Holekamp, NM; Siddiqi, OK | 1 |
| Huang, M; Liu, R; Ouyang, Q; Tang, C; Wang, C | 1 |
| Amer, F; Cryer, B; Goldstein, JL; Hunt, B | 1 |
| Augustyniak, ME; Cochran, ED; Ellis, JL; Fang, X; Garvey, DS; Janero, DR; Letts, LG; Martino, AM; Melim, TL; Murty, MG; Richardson, SK; Schroeder, JD; Selig, WM; Trocha, AM; Wexler, RS; Wey, SJ; Young, DV; Zemtseva, IS; Zifcak, BM | 1 |
| Bolieva, LZ; Dzhioev, FK; Kakabadze, SA | 1 |
| Chen, H; Clyne, S; Han, E; Harris, R; Lehrich, R; Lewis, J; Middleton, J; Rodby, R; Schulman, G; Shyr, Y; Sika, M; Sinsakul, M | 1 |
| Johns, EJ; Knight, S | 1 |
| Carlsson, T; Karlsson, JO; Petersen, A; Zetterberg, M | 1 |
| Boon, EM; Kemper, K; Peppelenbosch, MP; Richel, DJ; Tuynman, JB; Vermeulen, L; Zwinderman, AH | 1 |
| Boutary, M; Dorr, LD; Long, WT; Raya, J; Sirianni, LE | 1 |
| Xiao, H; Yang, CS | 1 |
| Ahmadiani, A; Pourahmad, J; Rasekh, HR; Rezaei, M | 1 |
| Dabhi, JK; Mehta, A; Solanki, JK | 1 |
| Falk, GW; Jankowski, J | 1 |
| Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P | 1 |
| Han, JA; Kim, SR; Lee, ME; Park, JH; Park, JS; Park, SC | 1 |
| Broughton, DE; Gazelle, GS; Hur, C; Kong, CY; Ozanne, EM; Richards, EB; Truong, T | 1 |
| Abid, KM; Ardestani, MS; Hemmati, A; Mehrab, H; Moghaddam, HF; Nazari, Z | 1 |
| Aisenberg, J; Bamji, N; Bodian, C; Brooks, A; Cohen, L; Desai, J; Dikman, A; Miller, K; Sanyal, S; VON Althann, C; Whitson, M | 1 |
| Bartra, J; Muñoz-Cano, R; Picado, C; Valero, A; Vennera, MC | 1 |
| Baker, LD; Breitner, JC; Milne, G; Montine, TJ; Sonnen, JA | 1 |
| De Caterina, R; Renda, G; Romano, M; Zurro, M | 1 |
| Jobe, BA; Lombard, CM; Triadafilopoulos, G | 1 |
| Decker, SA; Fellows-Mayle, W; Fujita, M; Hamilton, RL; Kohanbash, G; Komohara, Y; Ohlfest, JR; Okada, H | 1 |
| Gravitz, L | 1 |
| Brzozowski, T; Konturek, SJ; Kwiecien, S; Mazurkiewicz-Janik, M; Pajdo, R; Pawlik, M; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z | 1 |
| Berger, MF; Chan, FK; Goldstein, JL; Lanas, A; Nguyen, H; Peura, D; Sands, GH; Scheiman, JM; Wilcox, CM | 1 |
| Brzozowski, T; Drozdowicz, D; Karczewska, E; Konturek, SJ; Krzysiek-Maczka, G; Pajdo, R; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z; Urbanczyk, K; Zwolinska-Wcislo, M | 1 |
| Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
| Bertagnolli, MM; Chan, AT; Hawk, ET; Hsu, M; Zauber, AG | 1 |
| Davis, JM; Torrey, EF | 1 |
| Borodulina, EV; Kulakova, NV; Semiglazova, TA; Soloviev, MA; Udut, VV | 1 |
| Avril, S; Bronger, H; Cerny, C; Kiechle, M; Kraeft, S; Schmitt, M; Schwarz-Boeger, U; Stöckel, A | 1 |
| Blackler, R; Bolla, M; Ongini, E; Syer, S; Wallace, JL | 1 |
| Ockenga, J | 1 |
| Manzano, A; Pérez-Segura, P | 1 |
| Choi, SS; Han, JA; Jung, YJ; Kim, SR; Kim, WJ; Lee, ME; Lee, S | 1 |
| Chan, AP; Chan, SK; Hasan, MR; Jin, C; Kim, J; Kim, YB; Le, ND; Rahman, M; Selvarajan, K; Tai, IT | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
| Dong, L; Jurban, BJ; Sharma, NP; Smith, WL | 1 |
| Sifferlin, A | 1 |
| Donnan, PT; Guthrie, B; Jackson, C; Lipworth, BJ; Morales, DR; Santiago, VH | 1 |
| Kim, YG; Núñez, G; Shibuya, A; Totsuka, N; Udayanga, KG; Weinberg, JB | 1 |
| El-Azab, MF; El-Sayed, RM; Moustafa, YM | 1 |
| Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY | 1 |
| Bordignon, J; Cecchini, R; da Silva, RV; de Freitas, RC; Goldenberg, S; Lovo-Martins, MI; Malvezi, AD; Martins-Pinge, MC; Neto, EC; Panis, C; Pinge-Filho, P; Tatakihara, VL; Yamada-Ogatta, SF; Zanluqui, NG | 1 |
| Dennis, EA; Glass, CK; Gosselin, D; Norris, PC; Reichart, D | 1 |
| Ch Yiannakopoulou, E | 1 |
| Barnholtz-Sloan, JS; Chen, Y; Dawson, DM; Fink, SP; Kopelovich, L; Kresak, A; Lawrence, EG; Markowitz, SD; Willis, JE; Yang, P; Zhang, Y | 1 |
| Li, C; Raikwar, NS; Santillan, DA; Santillan, MK; Thomas, CP | 1 |
| Aguilar, MI; Benítez, WV; Bye, R; Calzada, F; Colín, A; Ríos-Gómez, R | 1 |
| Aznaouridis, K; Bratsas, A; Dima, I; Ioakeimidis, N; Stefanadis, C; Tousoulis, D; Vlachopoulos, C; Xaplanteris, P | 1 |
| Di Franco, M; Frati, L; Guarino, ML; Guzzo, MP; Massimi, I; Pulcinelli, FM; Temperilli, F; Valesini, G | 1 |
| Pikovsky, O; Rimon, G; Ruzov, M; Stepensky, D | 1 |
| Lanas, Á | 1 |
| Kanbayashi, Y; Konishi, H | 1 |
| Lynch, PM | 1 |
| Dash, S; Kar, D; Ray, M; Sahrawat, TR; Shahbazi, S; Singh, S | 1 |
| Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY | 1 |
| Abdellatif, KR; Azouz, AA; Fadaly, WA | 1 |
| Agrawal, R; Assaiya, A; Banerjee, T; Jain, N; Kumar, A; Manivannan, E; Mufti, I; Parmar, HS; Tiwari, S | 1 |
| Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY | 1 |
| Bauk, L; Drmic, D; Klicek, R; Kokot, A; Luetic, K; Seiwerth, S; Sikiric, P; Stupnisek, M; Vcev, A; Vitaic, S | 1 |
| Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM | 1 |
| Ghazi, N; Meftah, M; Ramkumar, PN; Ranawat, AS; Ranawat, CS; White, PB | 1 |
| De Blay, F; Guenard-Bilbaut, L; Metz-Favre, C; Schaller, A | 1 |
| Brown, P; Hawk, E; Maresso, KC | 1 |
| Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| Antman, EM | 1 |
| Alberts, DS; Hammock, BD; Lance, P; Martinez, JA; Roe, DJ; Schriewer, A; Thompson, PA; Wertheim, BC; Yang, J | 1 |
| Brown, MD; Cook, MD; Grimm, H; Kretzschmar, J | 1 |
| Madka, V; Mohammed, A; Rao, CV; Yarla, NS | 1 |
| Buschiazzo, HO; Cañás, M; Dorati, CM; Mordujovich-Buschiazzo, P; Prozzi, GR; Urtasun, MA | 1 |
| Antunes, DM; Corrêa, L; DE Oliveira, APL; Duarte, CME; Fernandes, KPS; Guimarães, DM; Miguita, L; Nunes, FD; Rodrigues, MFSD | 1 |
| Ibi, K; Imai, K; Kihara, T; Nejishima, H; Ogawa, H; Senshu, M; Takeda, Y; Yonezawa, Y | 1 |
| Anderson, AJ; Dong, L; Malkowski, MG | 1 |
| Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C | 1 |
| Hibbeln, JR; Rapoport, SI | 1 |
| Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ | 1 |
| Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M | 1 |
| Rapoport, SI | 1 |
| Dreger, P; Eckstein, V; Ge, J; Gong, W; Hückelhoven-Krauss, A; Kleist, C; Müller-Tidow, C; Neuber, B; Ni, M; Sauer, T; Schmitt, A; Schmitt, M; Schubert, ML; Sellner, L; Wang, L; Wang, S; Xia, R; Yang, M | 1 |
| Brox, R; Hackstein, H | 1 |
| Ghosh, S | 1 |
| Anaya, FJ; Henry, K; Hong, J; Innis, RB; Kim, MJ; Lee, JH; Liow, JS; Manly, LS; Pike, VW; Santamaria, JAM; Shetty, HU; Shrestha, S; Telu, S; Zanotti-Fregonara, P; Zoghbi, SS | 1 |
| Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC | 1 |
| Arwa, F; Ganai, SA; Lone, A; Malik, FA; Rajamanikandan, S; Shah, BA | 1 |
42 review(s) available for celecoxib and aspirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular Diseases; Humans; Inflammation; Neoplasms; Skin Diseases | 2019 |
COX-2 inhibitors and the gastrointestinal tract.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Drug Interactions; Humans; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rodentia; Sulfonamides; Sulfones | 2001 |
[Safety of specific cyclo-oxygenase 2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Humans; Incidence; Lactones; Netherlands; Peptic Ulcer; Prospective Studies; Pyrazoles; Sulfonamides; Sulfones | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome | 2001 |
Familiar drugs may prevent cancer.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticarcinogenic Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Folic Acid; Humans; Male; Neoplasms; Pyrazoles; Raloxifene Hydrochloride; Sulfonamides; Tamoxifen; Vitamin A | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Fever; Hemorrhage; Humans; Isoenzymes; Kidney Diseases; Lactones; Membrane Proteins; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Humans; Lactones; Middle Aged; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Venous Thrombosis | 2001 |
COX-2 inhibitors: no pain, no heart gain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2001 |
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Female; Humans; Male; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Isoenzymes; Lactones; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones | 2002 |
[Neutrophil-endothelium interaction].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Adhesion; Cell Adhesion Molecules; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Gastric Mucosa; Humans; Indomethacin; Isoenzymes; Membrane Proteins; Microcirculation; Neutrophils; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2002 |
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Topics: Arthritis; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Humans; Isoenzymes; Kidney; Lactones; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2002 |
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lactones; Male; Meta-Analysis as Topic; Osteoarthritis; Peptic Ulcer; Prevalence; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones | 2003 |
Chemoprevention of colorectal cancer: slow, steady progress.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Colorectal Neoplasms; Folic Acid; Humans; Pyrazoles; Sulfonamides; Sulindac | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Osteoarthritis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Drug Hypersensitivity; Humans; Isoenzymes; Lactones; Membrane Proteins; Meta-Analysis as Topic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2003 |
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Combinations; Gastrointestinal Diseases; Humans; Isoenzymes; Lipoxygenase Inhibitors; Long-Term Care; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrroles; Sulfonamides | 2004 |
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoenzymes; Membrane Proteins; Nitric Oxide Donors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach Ulcer; Sulfonamides | 2004 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma; Celecoxib; Colorectal Neoplasms; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Pyrazoles; Sulfonamides; Sulindac | 2006 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Decision Making; Drug Synergism; Evidence-Based Medicine; Humans; Middle Aged; Myocardial Infarction; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Stomach Diseases; Sulfonamides | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aspirin; Benzothiazoles; Bipolar Disorder; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Dopamine Agonists; Estrogens; Fatty Acids, Omega-3; Folic Acid; Humans; Mianserin; Minocycline; Mirtazapine; Pramipexole; Pregnenolone; Pyrazoles; Randomized Controlled Trials as Topic; Schizophrenia; Sulfonamides; Treatment Outcome; Vitamin B Complex | 2012 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulindac | 2012 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Hypersensitivity; Humans; Pyrazoles; Respiratory Tract Diseases; Risk; Sulfonamides | 2014 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Drug Synergism; Female; Humans; Salicylates; Tamoxifen | 2015 |
[Gastrointestinal bleeding].
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecoxib; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Gastrointestinal Hemorrhage; Hemorrhagic Disorders; Hemostatic Techniques; Humans; Ligation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Thrombophilia | 2015 |
Chemoprevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colectomy; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Eflornithine; Evidence-Based Medicine; Humans; Prophylactic Surgical Procedures; Remission Induction; Sulindac | 2016 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Child, Preschool; Chronic Disease; Chronic Pain; Fenoprofen; Humans; Ibuprofen; Lactones; Meloxicam; Methoxsalen; Naproxen; Randomized Controlled Trials as Topic; Sulfones; Thiazines; Thiazoles | 2017 |
Incidence of Heterotopic Ossification Following a Multimodal Pain Protocol in Total Hip Arthroplasty With the Posterior Approach.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Ossification, Heterotopic; Osteoarthritis, Hip; Pain, Postoperative; Radiography; Reproducibility of Results; Retrospective Studies; Risk Factors; Sex Factors; United States; Young Adult | 2018 |
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Celecoxib; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Naproxen; Neoplasm Recurrence, Local | 2018 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interactions; Humans; Ibuprofen; Naproxen; Risk Factors | 2018 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Dementia; Hemorrhage; Humans; Incidence; Lactones; Middle Aged; Myocardial Infarction; Naproxen; Randomized Controlled Trials as Topic; Stroke; Sulfones | 2020 |
THERAPEUTIC TARGETING OF BRAIN ARACHIDONIC ACID CASCADE IN BIPOLAR DISORDER BY LOW DOSE ASPIRIN AND CELECOXIB.
Topics: Arachidonic Acid; Aspirin; Bipolar Disorder; Brain; Celecoxib; Humans; Randomized Controlled Trials as Topic | 2020 |
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins | 2021 |
Aspirin and celecoxib may help to rectify a neurotransmission imbalance in bipolar disorder.
Topics: Animals; Antimanic Agents; Aspirin; Bipolar Disorder; Celecoxib; Humans; Rats; Synaptic Transmission | 2021 |
Metabolomic Studies for Metabolic Alterations Induced by Non-Steroidal Anti-Inflammatory Drugs: Mini Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Humans; Ibuprofen; Inflammation; Metabolome; Metabolomics | 2021 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Child; Chronic Disease; Diclofenac; Flurbiprofen; Humans; Ibuprofen; Infant; Ketoprofen; Ketorolac; Meloxicam; Naproxen; Niflumic Acid; Pain | 2022 |
35 trial(s) available for celecoxib and aspirin
| Article | Year |
|---|---|
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Endoscopy; Female; Humans; Knee Joint; Male; Middle Aged; Naproxen; Osteoarthritis; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Safety; Severity of Illness Index; Stomach Ulcer; Sulfonamides; Thromboxane B2; Treatment Outcome | 1998 |
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Eicosanoids; Female; Humans; Ibuprofen; In Vitro Techniques; Inflammation; Isoenzymes; Lipid Peroxidation; Lipopolysaccharides; Male; Membrane Proteins; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Peptic Ulcer; Proportional Hazards Models; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2000 |
Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Insulin; Insulin Resistance; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Reference Values; Sulfonamides | 2001 |
The safety of celecoxib in patients with aspirin-sensitive asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Hypersensitivity; Drug Synergism; Female; Humans; Male; Middle Aged; Pyrazoles; Sulfonamides | 2002 |
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.
Topics: Adenosine Diphosphate; Adolescent; Adult; Arachidonic Acid; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Interactions; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2 | 2002 |
Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2.
Topics: Acetylcholine; Aspirin; Body Mass Index; Celecoxib; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Synergism; Endothelium, Vascular; Estradiol; Female; Humans; Isoenzymes; Kinetics; Laser-Doppler Flowmetry; Membrane Proteins; Middle Aged; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Triglycerides; Vasodilation | 2002 |
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Hypersensitivity; Female; Humans; Isoenzymes; Leukotriene E4; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2003 |
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastric Mucosa; Humans; Isoenzymes; Lipoxins; Male; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2003 |
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Celecoxib; Computer Graphics; Cross-Over Studies; Cyclooxygenase Inhibitors; Cysteine; Double-Blind Method; Drug Eruptions; Female; Humans; Lactones; Leukotriene E4; Leukotrienes; Male; Middle Aged; Multivariate Analysis; Naproxen; Prospective Studies; Pyrazoles; Serine Endopeptidases; Skin; Sulfonamides; Sulfones; Treatment Outcome; Tryptases; Urticaria | 2003 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cross Reactions; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Female; Forced Expiratory Volume; Hemodynamics; Humans; Isoenzymes; Lactones; Male; Meloxicam; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recurrence; Rhinitis, Allergic, Perennial; Single-Blind Method; Sulfonamides; Sulfones; Thiazines; Thiazoles; Urticaria | 2004 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Osteoarthritis; Pyrazoles; Sulfonamides; Sulfones | 2005 |
Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
Topics: Adult; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bronchial Spasm; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Female; Humans; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rhinitis; Single-Blind Method; Sulfonamides; Treatment Outcome; Urticaria | 2005 |
The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Blood Pressure; Celecoxib; Clinical Chemistry Tests; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Indomethacin; Kidney; Kidney Function Tests; Middle Aged; Pyrazoles; Sulfonamides | 2006 |
The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2006 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Celecoxib; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Dose-Response Relationship, Drug; Female; Headache; Humans; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Kidney Diseases; Male; Middle Aged; Pyrazoles; Secondary Prevention; Sulfonamides | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Kidney Diseases; Male; Middle Aged; Pyrazoles; Secondary Prevention; Sulfonamides | 2006 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Myocardial Ischemia; Osteoarthritis; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome | 2006 |
Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Single-Blind Method; Sulfonamides | 2006 |
Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Pyrazoles; Single-Blind Method; Sulfonamides | 2008 |
Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Naproxen; Pyrazoles; Random Allocation; Stomach Ulcer; Sulfonamides | 2008 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Confidence Intervals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Retrospective Studies; Risk Factors; Stomach Ulcer; Sulfonamides; United States | 2007 |
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Celecoxib; Creatinine; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Middle Aged; Models, Statistical; Pilot Projects; Proteinuria; Pyrazoles; Quinapril; Sulfonamides; Tetrahydroisoquinolines | 2007 |
Multimodal analgesia without parenteral narcotics for total knee arthroplasty.
Topics: Administration, Oral; Amides; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthetics, Local; Arthroplasty, Replacement, Knee; Aspirin; Catheters, Indwelling; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Femoral Nerve; Hip Joint; Humans; Injections, Intra-Articular; Isoxazoles; Ketorolac; Nerve Block; Pain Measurement; Pain, Postoperative; Prospective Studies; Pyrazoles; Ropivacaine; Sulfonamides | 2008 |
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administration Schedule; Female; Gastric Mucosa; Humans; Male; Middle Aged; Naproxen; Peptic Ulcer; Pilot Projects; Pyrazoles; Sulfonamides; Ticlopidine; Young Adult | 2009 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Therapy, Combination; F2-Isoprostanes; Female; Humans; Male; Naproxen; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome | 2010 |
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; Lipoxins; Middle Aged; Myocardial Ischemia; Osteoarthritis; Placebo Effect; Pyrazoles; Sulfonamides | 2010 |
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Osteoarthritis; Prospective Studies; Pyrazoles; Sulfonamides | 2011 |
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Male; Middle Aged; Placebos; Pyrazoles; Sulfonamides | 2012 |
Correction of endothelial dysfunction in patients with arterial hypertension.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Celecoxib; Cyclooxygenase Inhibitors; Endothelium, Vascular; Humans; Hypertension; Intercellular Adhesion Molecule-1; Middle Aged; Pyrazoles; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Ultrasonography; Vasodilation | 2011 |
Arterial stiffening and systemic endothelial activation induced by smoking: The role of COX-1 and COX-2.
Topics: Adult; Analysis of Variance; Aspirin; Cardiovascular Diseases; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Reference Values; Risk Assessment; Smoking; Treatment Outcome; Vascular Stiffness | 2015 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Middle Aged; Naproxen; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Recurrence; Secondary Prevention | 2017 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Treatment Outcome | 2018 |
Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Topics: Adenomatous Polyps; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Pressure; Celecoxib; Colon; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Male; Middle Aged; Oxylipins; Placebo Effect; Polyps; Selenium | 2018 |
143 other study(ies) available for celecoxib and aspirin
| Article | Year |
|---|---|
A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzene Derivatives; Cyclooxygenase 2; Ethylenes; Isoenzymes; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Stereoisomerism; Structure-Activity Relationship | 2004 |
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Topics: Administration, Oral; Alkynes; Analgesics; Animals; Arachidonate 15-Lipoxygenase; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Lipoxygenase Inhibitors; Mice; Models, Molecular; Pain Measurement; Rats; Structure-Activity Relationship | 2006 |
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhibitors; Drug Design; Edema; Female; Foot; Formaldehyde; Inflammation; Male; Rats; Rats, Sprague-Dawley; Thiazoles | 2008 |
'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors.
Topics: Animals; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; Guinea Pigs; Indenes; Male; Models, Molecular; Molecular Structure; Muscles; Naphthalenes; Resveratrol; Stilbenes; Structure-Activity Relationship | 2007 |
Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Design; Humans; Imides; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Prostaglandin-Endoperoxide Synthases; Structure-Activity Relationship; Sulfones | 2007 |
Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers.
Topics: Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Structure-Activity Relationship | 2008 |
Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
Topics: Acrylates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Esters; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Rats; Serum; Structure-Activity Relationship | 2008 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 1-(4-methanesulfonylphenyl)-5-aryl-1H-pyrazol-3-carboxylic acids: synthesis, nitric oxide release studies and anti-inflammatory activities.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Esters; Hydrazines; Inflammation; Molecular Structure; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Pyrazoles; Rats; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Carrageenan; Celecoxib; Edema; Inflammation; Nitric Oxide Donors; Pyrazoles; Pyridines; Rats; Structure-Activity Relationship; Sulfonamides | 2008 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Esters; Hydrazines; Inhibitory Concentration 50; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Pyrazoles; Pyrrolidines; Rats; Sulfonamides | 2008 |
Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Design; Edema; Foot; Lipoxygenase Inhibitors; Molecular Structure; Pyrazoles; Pyridones; Rats; Structure-Activity Relationship; Sulfonamides | 2008 |
Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Ibuprofen; Inflammation; Inhibitory Concentration 50; Isoenzymes; Lipoxygenase Inhibitors; Models, Chemical; Pyridones; Rats | 2009 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Azo Compounds; Cyclooxygenase Inhibitors; Edema; Foot; Humans; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Prostaglandin-Endoperoxide Synthases; Rats; Sheep | 2009 |
COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Lauraceae; Lipoxygenase Inhibitors; Platelet Aggregation Inhibitors; Rabbits | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Humans; Hydrogen-Ion Concentration; Ibuprofen; Inhibitory Concentration 50; Molecular Structure; Nitric Oxide; Nitric Oxide Donors; Piperidines; Prodrugs; Pyrazoles; Rats; Sheep; Structure-Activity Relationship; Sulfonamides | 2010 |
Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Humans; Hydrazines; Nitric Oxide; Nitric Oxide Donors; Nitrosamines; Prodrugs; Pyrazoles; Rats; Sulfonamides | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Models, Molecular; Pyrazoles; Rats; Sulfonamides | 2011 |
N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.
Topics: Animals; Catalytic Domain; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Humans; Indoles; Indomethacin; Kinetics; Models, Molecular; Recombinant Proteins; Schiff Bases; Sheep; Solutions; Structure-Activity Relationship | 2012 |
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Ibuprofen; Microscopy, Confocal; Protein Binding; Pyrazoles; Rhodamines; Structure-Activity Relationship; Sulfonamides | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity | 2013 |
Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Chromones; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Indoles; Mice; Models, Molecular; Molecular Structure; Pain; Pain Measurement; Pyrazoles; Structure-Activity Relationship | 2014 |
Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Edema; Mice; Models, Molecular; Molecular Structure; Rats; Structure-Activity Relationship | 2014 |
Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Male; Mice; Molecular Docking Simulation; Oxadiazoles; Protein Conformation; Rats; Stomach Ulcer; Structure-Activity Relationship; Substrate Specificity | 2014 |
1-(4-Methane(amino)sulfonylphenyl)-3-(4-substituted-phenyl)-5-(4-trifluoromethylphenyl)-1H-2-pyrazolines/pyrazoles as potential anti-inflammatory agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrazoles; Structure-Activity Relationship | 2015 |
Synthesis of new thiazolo-celecoxib analogues as dual cyclooxygenase-2/15-lipoxygenase inhibitors: Determination of regio-specific different pyrazole cyclization by 2D NMR.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 15-Lipoxygenase; Cattle; Celecoxib; Chemistry Techniques, Synthetic; Cyclization; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Male; Pyrazoles; Rats; Stereoisomerism; Thiazoles; Ulcer | 2016 |
Cyclooxygenase-2 and 15-lipoxygenase inhibition, synthesis, anti-inflammatory activity and ulcer liability of new celecoxib analogues: Determination of region-specific pyrazole ring formation by NOESY.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 15-Lipoxygenase; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Lipoxygenase Inhibitors; Models, Molecular; Molecular Structure; Pyrazoles; Structure-Activity Relationship | 2016 |
Design, synthesis, biological evaluation, and molecular docking of chalcone derivatives as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Chalcone; Cyclooxygenase 2; Drug Design; Edema; Interleukin-6; Lipopolysaccharides; Macrophages; Mice; Molecular Docking Simulation; Protein Structure, Tertiary; RAW 264.7 Cells; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xylenes | 2017 |
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
Topics: Anti-Inflammatory Agents; Antioxidants; Coumarins; Cyclooxygenase Inhibitors; Lipid Peroxidation; Molecular Structure; Plant Extracts; Tetrazoles; Tetrazolium Salts; Thiazoles | 2017 |
Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Models, Molecular; Molecular Structure; RAW 264.7 Cells; Sheep; Structure-Activity Relationship; Urochordata | 2019 |
Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Carrageenan; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Design; Edema; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Structure; Pyrrolidines; Structure-Activity Relationship | 2020 |
Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.
Topics: | 2021 |
COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 1999 |
Colon cancer prevention. Worth the trouble.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colonic Neoplasms; Diet; Female; Folic Acid; Humans; Male; Pyrazoles; Sulfonamides; Vitamins | 1999 |
Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2001 |
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Heart; Isoenzymes; Male; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Sulfonamides; Thromboxane A2 | 2001 |
Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Topics: Acetylcholine; Animals; Arachidonic Acid; Aspirin; Benzofurans; Blood Flow Velocity; Celecoxib; Coronary Circulation; Coronary Thrombosis; Coronary Vessels; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoprostenol; Isoenzymes; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane-A Synthase; Time Factors; Vasodilation; Vasomotor System | 2001 |
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; In Vitro Techniques; Isoenzymes; Membrane Proteins; Microscopy, Electron; Peptide Fragments; Plaque, Amyloid; Prostaglandin-Endoperoxide Synthases; Protein Structure, Secondary; Pyrazoles; Sulfonamides | 2001 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Kidney; Male; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Prostaglandins F; Pyrazoles; Rabbits; Salicylates; Sulfonamides; Thromboxane B2 | 2002 |
Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.
Topics: Aedes; Amides; Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Echinacea; Ibuprofen; Isoenzymes; Lactones; Lethal Dose 50; Naproxen; Phytotherapy; Plant Extracts; Plant Roots; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
[Coxib spares the stomach. This is true also for patients with preventive aspirin administration].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Drug Therapy, Combination; Humans; Osteoarthritis; Pyrazoles; Randomized Controlled Trials as Topic; Stomach Ulcer; Sulfonamides | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Sulfonamides | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lactones; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
Blue rubber bleb nevus syndrome.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colonic Diseases; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Hemangioma, Cavernous; Humans; Male; Otorhinolaryngologic Neoplasms; Pyrazoles; Sulfonamides; Syndrome | 2002 |
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage.
Topics: Animals; Aspirin; Celecoxib; Cell Adhesion; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Resistance; Gastric Mucosa; Hydroxyeicosatetraenoic Acids; Isoenzymes; Lactones; Leukocytes; Lipoxins; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones | 2002 |
[When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Clinical Trials as Topic; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Peptic Ulcer Hemorrhage; Pyrazoles; Stomach Ulcer; Sulfonamides | 2003 |
Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Gene Expression Regulation, Enzymologic; Hepatocytes; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Pyrazoles; Rats; RNA, Messenger; Sulfonamides; Tumor Cells, Cultured | 2003 |
Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Dose-Response Relationship, Drug; Drug Interactions; Epoprostenol; Kidney; Mercuric Chloride; Pyrazoles; Rabbits; Sulfonamides; Thromboxanes | 2003 |
Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Single-Blind Method; Sulfonamides; Treatment Outcome | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Family Practice; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypertension; Monitoring, Physiologic; Osteoarthritis, Knee; Pyrazoles; Risk Assessment; Sensitivity and Specificity; Stroke; Sulfonamides | 2003 |
Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Acetaminophen; Anesthetics, Inhalation; Animals; Aspirin; Celecoxib; Coronary Circulation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diazoxide; Dogs; Hemodynamics; Ischemic Preconditioning, Myocardial; Isoenzymes; Isoflurane; Membrane Proteins; Myocardial Infarction; Myocardium; Potassium Channels; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat.
Topics: Animals; Aspirin; Carrageenan; Celecoxib; Consciousness; Cyclooxygenase Inhibitors; Edema; Gastric Mucosa; Indomethacin; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2004 |
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Membrane; Cell Survival; Cytoplasm; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Flow Cytometry; Fluorescein-5-isothiocyanate; Granzymes; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Immunotherapy; Insulin; Kinetics; Lactones; Models, Chemical; Neoplasms; Pioglitazone; Pyrazoles; Serine Endopeptidases; Sulfonamides; Sulfones; Thiazolidinediones; Up-Regulation | 2004 |
Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nonprescription Drugs; Pyrazoles; Sulfonamides | 2004 |
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neoplasms; Computer Simulation; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Humans; Male; Markov Chains; Middle Aged; Pyrazoles; Quality-Adjusted Life Years; Sulfonamides | 2004 |
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Eicosanoids; Freund's Adjuvant; Gastric Mucosa; Isoenzymes; Lipoxins; Male; Membrane Proteins; Naproxen; Nitric Oxide; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Stomach Ulcer; Sulfonamides | 2004 |
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.
Topics: Acetylcholine; Animals; Aorta; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Hydroxyurea; Lipoxins; Lipoxygenase Inhibitors; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroarginine; Oligopeptides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Lipoxin; Sulfonamides; Vascular Resistance; Vasodilation; Vasodilator Agents | 2004 |
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; Databases as Topic; Esophageal Neoplasms; Female; Humans; Incidence; Lactones; Logistic Models; Male; Pyrazoles; Quebec; Risk Factors; Sex Factors; Sulfonamides; Sulfones | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Isoenzymes; Membrane Proteins; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Sulfonamides | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Flurbiprofen; Ibuprofen; Isoenzymes; Lactones; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Thrombosis | 2004 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interactions; Gastrointestinal Diseases; History, 20th Century; History, 21st Century; Humans; Lactones; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2005 |
A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Celecoxib; Dose-Response Relationship, Drug; Humans; Ibuprofen; Platelet Activation; Platelet Aggregation; Pyrazoles; Sulfonamides; Thrombelastography | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Prostanoids as friends, not foes: further evidence from the interference by cycloxygenase-inhibitory drugs when inducing tolerance to experimental arthritigens in rats.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Tolerance; Female; Inflammation; Injections, Subcutaneous; Lipids; Pain; Prednisolone; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; Squalene; Sulfonamides; Time Factors | 2005 |
Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Glutathione; Inflammation; Male; Malondialdehyde; Plant Bark; Plant Extracts; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; Salix; Sulfonamides; Superoxide Dismutase | 2005 |
Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Heart Diseases; Humans; Ibuprofen; Membrane Proteins; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides | 2005 |
Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen.
Topics: Acetaminophen; Aspirin; Asthma; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Leukotriene E4; Middle Aged; Pyrazoles; Sulfonamides | 2006 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celecoxib; Cell Growth Processes; Colonic Neoplasms; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Pyrazoles; Pyrroles; Rats; Rats, Inbred F344; Sulfonamides | 2006 |
Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Quebec; Retrospective Studies; Sulfonamides; Treatment Outcome | 2007 |
Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation.
Topics: Animals; Apoptosis; Aspirin; Caspase 3; Caspase 8; Caspases; Celecoxib; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Enzymologic; Male; Membrane Proteins; Oncogene Protein v-akt; Phosphorylation; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Stem Cells; Sulfonamides | 2006 |
[Effects of selective and non-selective cyclooxygenase-2 inhibitor on the growth of colon cancer cells].
Topics: Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Meloxicam; Pyrazoles; Sulfonamides; Thiazines; Thiazoles | 2006 |
Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.
Topics: Antineoplastic Agents; Aspirin; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Endothelial Cells; Humans; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Salicylic Acid; Sulfonamides | 2006 |
Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Drug Hypersensitivity; Eicosanoids; Female; Humans; Pyrazoles; Sinusitis; Sulfonamides; Urticaria | 2006 |
Genetic tools to tailor cancer prevention by NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gastrointestinal Tract; Humans; Models, Biological; Neoplasms; Pyrazoles; Sulfonamides | 2006 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Pyrazoles; Quebec; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones | 2007 |
Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Interactions; Gastric Mucosa; Hydrophobic and Hydrophilic Interactions; Male; Phosphatidylcholines; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides | 2007 |
12 things you should know about pain relievers. A dozen take-home messages about the pills that take the hurt away.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Celecoxib; Humans; Naproxen; Pharmacogenetics; Pyrazoles; Sulfonamides | 2007 |
Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-X Protein; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides; Survivin; Transcription Factor RelA; Up-Regulation | 2007 |
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Comorbidity; Cyclooxygenase 2 Inhibitors; Drug Interactions; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Sulfonamides | 2007 |
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chemoprevention; Cyclooxygenase 2 Inhibitors; Female; Humans; Ibuprofen; Lactones; Logistic Models; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Ohio; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2007 |
[The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Safety of intravitreal injections in patients receiving warfarin anticoagulation.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aptamers, Nucleotide; Aspirin; Celecoxib; Choroidal Neovascularization; Drug Therapy, Combination; Eye Hemorrhage; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sulfonamides; Vascular Endothelial Growth Factor A; Vitreous Body; Warfarin | 2007 |
[Induction of NAG-1 gene expression in colon cancer cells by non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Meloxicam; Neoplasm Proteins; Pyrazoles; RNA, Messenger; Sulfonamides; Thiazines; Thiazoles | 2007 |
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Drug Synergism; Female; Gastric Mucosa; Humans; Hydroxamic Acids; Indomethacin; Male; Nitric Oxide Donors; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship; Sulfonamides | 2007 |
Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Celecoxib; Diethylnitrosamine; Esophageal Neoplasms; Liver Neoplasms; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2007 |
Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Topics: Animals; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Diuresis; Glomerular Filtration Rate; Hypertension; Kidney; Male; Membrane Proteins; Nitrates; Nitric Oxide; Nitric Oxide Donors; Prostaglandins; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Renal Circulation; Reperfusion Injury; Sodium; Sulfonamides; Time Factors | 2008 |
Intracellular effects of NSAIDs/ASA in oxidatively stressed human lens epithelial cells in culture.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Size; Cells, Cultured; Diclofenac; Epithelial Cells; Free Radical Scavengers; Glutathione; Humans; Hydrogen Peroxide; Indomethacin; Intracellular Membranes; Lens, Crystalline; Membrane Potential, Mitochondrial; Mitochondria; Oxidants; Oxidative Stress; Peroxides; Pyrazoles; Reactive Oxygen Species; Sulfonamides; Superoxides | 2008 |
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
Topics: Aspirin; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Phosphorylation; Pyrazoles; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sulfonamides; Transfection; Wnt Proteins | 2008 |
Involvement of subcellular organelles in inflammatory pain-induced oxidative stress and apoptosis in the rat hepatocytes.
Topics: Animals; Apoptosis; Aspirin; Celecoxib; Hepatocytes; Inflammation; Male; Organelles; Oxidative Stress; Pain; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2008 |
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Disease Models, Animal; Female; Hypercholesterolemia; Hypolipidemic Agents; Ibuprofen; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2008 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Precancerous Conditions; Pyrazoles; Sulfonamides; Treatment Outcome | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyclooxygenase Inhibitors; Disease Progression; Drug Therapy, Combination; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Precancerous Conditions; Pyrazoles; Risk Factors; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2008 |
Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner.
Topics: Aspirin; Caveolin 1; Celecoxib; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fibroblasts; Flurbiprofen; Humans; Ibuprofen; Kinetics; Models, Biological; NF-kappa B; Nitrobenzenes; Pyrazoles; Reactive Oxygen Species; Skin; Skin Aging; Sulfonamides; Tumor Suppressor Protein p53 | 2008 |
Patient preferences for the chemoprevention of colorectal cancer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neoplasms; Decision Making; Female; Humans; Male; Middle Aged; Patient Satisfaction; Pyrazoles; Sulfonamides | 2009 |
Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Inflammation; Male; Parkinson Disease; Pyrazoles; Rats; Rats, Wistar; Risk; Sulfonamides; Treatment Outcome | 2007 |
Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma.
Topics: Adult; Aspirin; Asthma; Bronchial Spasm; Celecoxib; Cyclooxygenase Inhibitors; Drug Hypersensitivity; Female; Forced Expiratory Volume; Humans; Pyrazoles; Sulfonamides | 2009 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celecoxib; Drug Therapy, Combination; Endoscopy; Esophageal Neoplasms; Fundoplication; Gastroesophageal Reflux; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Omeprazole; Pyrazoles; Quality of Life; Sulfonamides; Treatment Outcome | 2011 |
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Topics: Alleles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CD8-Positive T-Lymphocytes; Celecoxib; Chemokine CCL2; Chemokine CXCL10; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Glioma; Lysosomal-Associated Membrane Protein 1; Male; Mice; Mice, Inbred C57BL; Myeloid Cells; Pyrazoles; Sulfonamides; T-Lymphocytes, Cytotoxic | 2011 |
Chemoprevention: First line of defence.
Topics: Animals; Aspirin; Celecoxib; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal; Disease Progression; Female; Focal Adhesion Protein-Tyrosine Kinases; Genistein; Humans; Inflammation; Male; Matrix Metalloproteinase 2; Mice; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Polyamines; Precancerous Conditions; Prostatic Neoplasms; Pyrazoles; Risk Assessment; Sulfonamides | 2011 |
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Esophagitis, Peptic; Esophagus; Gastric Acid; Humans; Indomethacin; Male; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides | 2011 |
Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Load; Bacterial Translocation; Celecoxib; Chemokines; Colitis; Colon; Cyclooxygenase 2 Inhibitors; Enterococcus; Escherichia coli; Feces; Humans; Intestinal Mucosa; Intestines; Male; Microcirculation; Peroxidase; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Trinitrobenzenesulfonic Acid | 2011 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Topics: Aspirin; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Chemokine CXCL10; Chemokine CXCL9; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Indomethacin; Interferon-gamma; Pyrazoles; Sulfonamides; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2012 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Hypertension; Male; Naproxen; Nitrates; Obesity; Omeprazole; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rats, Zucker; Sulfonamides | 2012 |
A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.
Topics: Aspirin; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Early Detection of Cancer; Humans; Occult Blood; Pyrazoles; Sulfonamides | 2012 |
Cyclooxygenase-2 inhibitors modulate skin aging in a catalytic activity-independent manner.
Topics: Animals; Aspirin; Catalysis; Caveolin 1; Celecoxib; Collagen Type I; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation; Mice; Nitrobenzenes; Pyrazoles; Skin Aging; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.
Topics: Acetylation; Amino Acid Sequence; Amino Acid Substitution; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Flurbiprofen; Guanidine; Heme; Humans; Indomethacin; Kinetics; Models, Biological; Mutant Proteins; Mutation; Naproxen; Oxygen; Palmitic Acid; Peroxidase; Protein Multimerization; Pyrazoles; Substrate Specificity; Sulfonamides | 2013 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen; Pain; Pyrazoles; Risk Factors; Safety-Based Drug Withdrawals; Sulfonamides; United States; United States Food and Drug Administration | 2013 |
Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂.
Topics: Adoptive Transfer; Ampicillin; Animals; Anti-Bacterial Agents; Aspirin; Candida; Candidiasis; Cefoperazone; Celecoxib; Clindamycin; Cyclooxygenase Inhibitors; Dinoprostone; Dysbiosis; Feces; Gastrointestinal Tract; Inflammation; Lung; Macrophage Activation; Macrophages, Alveolar; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazoles; Sulfonamides | 2014 |
Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1.
Topics: Administration, Oral; Angiopoietin-1; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Experimental; Arthritis, Rheumatoid; Aspirin; Celecoxib; Disease Progression; Drug Therapy, Combination; gamma-Linolenic Acid; Inflammation; Linoleic Acids; Lipid Peroxidation; Male; Neovascularization, Pathologic; Oenothera biennis; Oxidative Stress; Plant Oils; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tumor Necrosis Factor-alpha | 2014 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; E2F2 Transcription Factor; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Liver; MCF-7 Cells; Mice; MicroRNAs; Pyrazoles; RNA, Messenger; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Line; Cell Survival; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Enzyme-Linked Immunosorbent Assay; Immunity, Innate; Immunohistochemistry; Interleukin-1beta; Myoblasts, Cardiac; Nitric Oxide; Pyrazoles; Rats; Sulfonamides; Transforming Growth Factor alpha; Transforming Growth Factor beta; Trypanosoma cruzi | 2014 |
Phospholipase A2 regulates eicosanoid class switching during inflammasome activation.
Topics: Animals; Aspirin; Celecoxib; Cell Line, Transformed; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Eicosanoids; Group IV Phospholipases A2; Hydroxyeicosatetraenoic Acids; Inflammasomes; Interleukin-1; Lipidoses; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrazoles; Receptors, Purinergic P2X7; Signal Transduction; Sulfonamides; Toll-Like Receptor 4 | 2014 |
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carcinogens; Celecoxib; Chemoprevention; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Hydroxyprostaglandin Dehydrogenases; Inflammation; Intestinal Mucosa; Membrane Proteins; Mice; Mice, Knockout; Pyrazoles; Sulfonamides; Sulindac | 2015 |
Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Hypoxia; Cell Line; Cells, Cultured; Chlorocebus aethiops; COS Cells; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Developmental; Humans; Pre-Eclampsia; Pregnancy; Pyrazoles; Recombinant Proteins; Solubility; Trophoblasts; Vascular Endothelial Growth Factor Receptor-1 | 2015 |
Evaluation of the diuretic activity in two Mexican medicinal species: Selaginella nothohybrida and Selaginella lepidophylla and its effects with ciclooxigenases inhibitors.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Diuretics; Indomethacin; Male; Mexico; Mice; Naproxen; Plant Extracts; Plants, Medicinal; Potassium; Selaginellaceae; Sodium | 2015 |
Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Megakaryocytes; Middle Aged; Multidrug Resistance-Associated Proteins; Naproxen; Osteoarthritis; Platelet Activation; Platelet Aggregation; RNA, Messenger | 2016 |
Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.
Topics: Adolescent; Adult; Animals; Aspirin; Binding, Competitive; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Biological; Platelet Aggregation; Young Adult | 2016 |
Predictive Factors for NSAIDs-related Gastrointestinal Toxicity: Can COX-2 Selective Inhibtor Prevent it?.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents; Aspirin; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Digestive System; Etodolac; Female; Humans; Logistic Models; Male; Middle Aged; Phenylpropionates; Protective Factors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Stomach Diseases; Stomach Ulcer | 2015 |
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies.
Topics: Anti-Inflammatory Agents; Aspirin; Binding Sites; Caffeic Acids; Celecoxib; Coumaric Acids; Cyclooxygenase 1; Cyclooxygenase 2; ERG1 Potassium Channel; Eugenol; Heart; Humans; Inflammation; Integrin alpha2; Protein Structure, Tertiary; Tirofiban; Tyrosine | 2016 |
(1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Gastric Mucosa; Ibuprofen; Indomethacin; Least-Squares Analysis; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Metabolomics; Piroxicam; Rats; Rats, Sprague-Dawley | 2016 |
Synthesis, Cyclooxygenase Inhibition, Anti-Inflammatory Evaluation, and Ulcerogenic Liability of New 1,3,5-Triarylpyrazoline Derivatives Possessing a Methanesulfonyl Pharmacophore.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Isoenzymes; Pyrazoles; Rats; Sheep; Structure-Activity Relationship; Thiophenes; Ulcer | 2016 |
Inhibition of Aβ(1-42)Oligomerization, Fibrillization and Acetylcholinesterase Activity by Some Anti-Inflammatory Drugs: An in vitro Study.
Topics: Acetylcholinesterase; Amyloid; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Butylated Hydroxyanisole; Celecoxib; Dexamethasone; Diclofenac; Indomethacin; Methylene Blue; Nitric Oxide; Peptide Fragments; Piroxicam; Rivastigmine; Singlet Oxygen | 2017 |
Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Celecoxib; Diclofenac; Esophageal Sphincter, Lower; Ibuprofen; Male; Peptide Fragments; Pressure; Proteins; Pylorus; Rats, Wistar | 2017 |
[Is celecoxib a safe alternative for the Fernand Widal syndrome?]
Topics: Adult; Aged; Aspirin; Asthma; Case-Control Studies; Celecoxib; Drug Hypersensitivity; Female; France; Humans; Male; Middle Aged; Nasal Polyps; Respiratory Function Tests; Retrospective Studies; Syndrome | 2018 |
NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; Humans; Neoplasm Recurrence, Local | 2018 |
The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Ibuprofen; Naproxen | 2018 |
The Effects of Exercise, Aspirin, and Celecoxib in an Atherogenic Environment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Celecoxib; Cells, Cultured; Epoprostenol; Exercise; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Nitric Oxide Synthase Type III; Stress, Mechanical; Thromboxane B2; Tumor Necrosis Factor-alpha | 2018 |
Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cell Survival; Chemokines; Cytokines; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-6; Mouth Neoplasms | 2019 |
Olive-Derived Hydroxytyrosol Shows Anti-inflammatory Effect without Gastric Damage in Rats.
Topics: Animals; Aspirin; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Gastric Mucosa; Indomethacin; Male; Olea; Phenylethyl Alcohol; Rats, Sprague-Dawley; Stomach; Stomach Ulcer | 2019 |
Arg-513 and Leu-531 Are Key Residues Governing Time-Dependent Inhibition of Cyclooxygenase-2 by Aspirin and Celebrex.
Topics: Animals; Arachidonic Acid; Arginine; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Enzyme Assays; Histidine; Hydroxyeicosatetraenoic Acids; Leucine; Mutagenesis, Site-Directed; Recombinant Proteins; Sf9 Cells; Stereoisomerism; Substrate Specificity; Time Factors | 2019 |
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2021 |
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Topics: Antigens, CD19; Apoptosis; Aspirin; Celecoxib; Cell Proliferation; Coculture Techniques; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Cytotoxicity, Immunologic; Humans; Immunotherapy, Adoptive; Inflammation Mediators; K562 Cells; Lymphocyte Activation; Lymphoma, B-Cell; Receptors, Chimeric Antigen; T-Lymphocytes | 2021 |
Physiologically relevant aspirin concentrations trigger immunostimulatory cytokine production by human leukocytes.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cytokines; Dinoprostone; Gene Expression Regulation; Humans; Indomethacin; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; Leukocytes; Male; Middle Aged; Toll-Like Receptors; Young Adult | 2021 |
Whole-Body PET Imaging in Humans Shows That
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ketoprofen; Positron-Emission Tomography | 2023 |
Comparative structural study of selective and non-selective NSAIDs against the enzyme cyclooxygenase-2 through real-time molecular dynamics linked to post-dynamics MM-GBSA and e-pharmacophores mapping.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Humans; Inflammation; Molecular Docking Simulation; Molecular Dynamics Simulation; Niflumic Acid; Pharmacophore; Sodium Salicylate | 2023 |